NDAORALTABLETPriority Review
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
ZELBORAF (vemurafenib) by Roche is protein kinase inhibitors [moa]. Approved for melanoma. First approved in 2011.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZELBORAF (vemurafenib) is an oral protein kinase inhibitor approved by the FDA in August 2011 for the treatment of melanoma and other BRAF-mutant cancers. It works by selectively inhibiting BRAF V600E mutations, blocking aberrant cell proliferation in tumors dependent on this oncogenic driver. The drug represents a targeted therapy approach that transformed treatment outcomes for patients with BRAF-mutant malignancies.
$0.0BPart D
6.1 years to LOEMechanism of Action
Protein Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications (1)
Clinical Trials (20)
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Started Sep 2024
86 enrolled
Hairy Cell Leukemia
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Started Oct 2023
165 enrolled
Colorectal Cancer Metastatic
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
Started Sep 2023
75 enrolled
Non-small-cell Lung Cancer
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Started Mar 2023
30 enrolled
Haematological MalignancyMelanomaThyroid Cancer, Papillary+9 more
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
Started Oct 2021
10 enrolled
Pancreas Cancer
Worked on ZELBORAF at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.